177Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177Lu-PSMA-I&T
RA Bundschuh, CH Pfob, G Wienand… - Clinical Nuclear …, 2023 - journals.lww.com
Abstract 177 Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been
optimized in terms of pharmacological and pharmacokinetic properties and may be therefore …
optimized in terms of pharmacological and pharmacokinetic properties and may be therefore …
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Background Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy
(RLT) with 177 Lu-labeled PSMA ligands has achieved remarkable results in advanced …
(RLT) with 177 Lu-labeled PSMA ligands has achieved remarkable results in advanced …
Peculiar Pattern of Response Following [225Ac] Ac-PSMA Therapy: A Case Report with 'PSA Pseudoregression'Response Pattern
A Al-Ibraheem, F Istatieh, AS Abdlkadir… - Nuklearmedizin …, 2024 - thieme-connect.com
Recent strides in theranostics have yielded radionuclide-labelled ligands targeting prostate-
specific membrane antigen (PSMA), resulting in paradigmatic advancements in the …
specific membrane antigen (PSMA), resulting in paradigmatic advancements in the …
Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
C Filss, A Heinzel, B Miiller, ATJ Vogg… - Nuklearmedizin …, 2018 - thieme-connect.com
Aim: In metastatic prostate cancer patients PSMA targeting radioligands have gained
significant impact as theranostic probes. In this study a correlation between total tumor …
significant impact as theranostic probes. In this study a correlation between total tumor …
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature …
DEK Sutherland, R Kashyap… - Therapeutic …, 2023 - journals.sagepub.com
Reported here is a case of rapidly progressive metastatic castration-resistant prostate
cancer treated with [177Lu] Lu-PSMA-617 in the setting of severe renal impairment and …
cancer treated with [177Lu] Lu-PSMA-617 in the setting of severe renal impairment and …
Dual-time-point posttherapy 177Lu-PSMA-617 SPECT/CT describes the uptake kinetics of mCRPC lesions and prognosticates patients' outcome
M Straub, J Kupferschläger, LMS Higuita… - Journal of Nuclear …, 2023 - Soc Nuclear Med
177Lu-PSMA-617 is an effective therapeutic option in metastasized castration-resistant
prostate cancer (mCRPC). However, some patients progress under treatment. We …
prostate cancer (mCRPC). However, some patients progress under treatment. We …
False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake
A 71-year-old man with advanced castration-resistant prostate cancer was referred to our
department for evaluation of prostate-specific membrane antigen (PSMA)–directed …
department for evaluation of prostate-specific membrane antigen (PSMA)–directed …
PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer
In patients with metastatic castration-resistant prostate cancer (mCRPC), radioligand therapy
targeting prostate-specific membrane antigen (PSMA-RLT) has been shown to be an …
targeting prostate-specific membrane antigen (PSMA-RLT) has been shown to be an …
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
N Mader, C Nguyen Ngoc, B Kirkgöze… - European Journal of …, 2023 - Springer
Purpose The currently used scheme for radioligand therapy (RLT) of patients with metastatic
castration-resistant prostate cancer (mCRPC) consists of 4–6 cycles of 6.0–7.4 GBq [177Lu] …
castration-resistant prostate cancer (mCRPC) consists of 4–6 cycles of 6.0–7.4 GBq [177Lu] …
PSMA radioligand therapy (PRLT) of metastatic castration-resistant prostate cancer: first results using the PSMA Inhibitor 617
H Kulkarni, A Singh, K Niepsch, C Schuchardt, R Baum - 2016 - Soc Nuclear Med
139 Objectives At our center, we have had experience with the PSMA inhibitor I&T in 56
patients with progressive metastatic castration-resistant prostate cancer (mCRPC). The …
patients with progressive metastatic castration-resistant prostate cancer (mCRPC). The …